Intrexon through collaboration is focused on the development of novel therapeutics for the treatment of a range of cancer types.  The Company is working to advance next-generation approaches in gene therapy, including viral-based delivery and non-viral adoptive cellular therapies. 
One area of focus today is CAR-T cell therapy which harnesses the power of the immune system to recognize and target tumor specific antigens and has shown early clinical promise.  Our novel gene and cell engineering technologies will be leveraged to realize the potential of genetically modified CAR-T cells by tightly controlling cell expansion and activation in the body, minimizing off-target effects and toxicity while maximizing therapeutic efficacy, through application of our RheoSwitch Therapeutic System®.